Status:
COMPLETED
MRD Detection by NGS in Pediatric B-ALL
Lead Sponsor:
The Children's Hospital of Zhejiang University School of Medicine
Conditions:
Acute Lymphoblastic Leukemia, Pediatric
Eligibility:
All Genders
Up to 18 years
Brief Summary
This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS)....
Detailed Description
Study Design, Patients, and Procedures This was a prospective, single-center, observational study conducted in children with ALL between November 2018 and June 2022. Children with newly diagnosed B-AL...
Eligibility Criteria
Inclusion
- Children with newly diagnosed B-ALL who undergone NGS of B-cell receptors
- Children older than 1 year receive treatment according to the ZJCH-ALL-2019 protocol, while children younger than 1 year receive treatment according to the infant leukemia protocol.
Exclusion
- B-cell acute lymphoblastic leukemia (B-ALL) patients who have not undergone high-throughput sequencing.
- Treated according to other protocols.
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT05973032
Start Date
November 1 2018
End Date
August 31 2022
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003